Avantor, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel Brennan from TD Cowen maintained a Hold rating on the stock and has a $9.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Daniel Brennan has given his Hold rating due to a combination of factors that balance improving company actions with lingering risks. Avantor modestly exceeded first-quarter expectations and management signaled greater confidence in a second-half recovery, supported by turnaround initiatives, easing comparisons, and signs that key end markets may be bottoming, all against a valuation that already reflects considerable pessimism.
At the same time, the reiterated 2026 outlook implies a need for faster growth beginning in the second quarter, which Brennan views as execution risk, especially given ongoing competitive pressures and recent pricing concessions that weighed on cash flow. With the VWR distribution and Bioscience & Medtech segments still posting organic declines and the path to a more durable upturn not yet fully proven, he maintains a neutral stance, trimming the price target from $10 to $9 while awaiting clearer evidence that operational improvements and market stabilization can translate into sustainable growth.
Brennan covers the Healthcare sector, focusing on stocks such as Agilent, Illumina, and Thermo Fisher. According to TipRanks, Brennan has an average return of 13.9% and a 46.49% success rate on recommended stocks.